|
Method of production of bacteriophage Method of production of bacteriophage comprises: inoculation with the bacterial culture of the host strain in the titre of 108-109 CFU/ml in the vessel for culturing on the slant having a layer thickness from 10 mm to 25 mm, culturing for 3-3.5 hours at optimum temperature for growth of the host strain culture, then on the resulting lawn of culture of the host strain the stock bacteriophage is inoculated in the titre 105-106 CFU/ml and cultured for 13-15 hours at the optimum temperature and the thickness of the air layer over the surface of the solid medium of 25 mm to 40 mm. the phage lysate is prepared and sucked into a sterile container, chloroform is added, incubated for 30-45 minutes with continuous shuttling. The supernatant is centrifuged and sterilised by filtration through the filter with a pore diameter of 0.2-0.22 microns. |
|
|
Method of assessment of activity of therapeutic and prophylactic preparations against natural smallpox comprises administering to an animal model of control and test groups in a predetermined scheme of suspension of the antiviral preparation under study, their intranasal infection with a strain of natural smallpox virus, incubation of the virus in animal bodies and determining the concentration of virus in the lungs of animals with the subsequent calculation of estimate values of decrease in the concentration of virus in lungs. The preparation is administered to animal bodies one day prior to infecting, on the day of infecting and every day during the time of the virus incubation. The animal models are used as outbred white mice ICR of different sexes weighing 7-9 g. The strain of natural smallpox virus is used as the strain India-3a deposited at the National Collection of pathogens of viral infections and rickettsioses of the Federal budget institution of science State Research Centre of Virology and Biotechnology "Vector" under the registration number V-45. |
|
|
Adenoviral vectors and related methods and applications Invention refers to biotechnology and represents an oncolytic adenoviral vector, a cell and a pharmaceutical composition containing the above vector, as well as applications of the above vectors in preparing a drug for treating cancer in an individual, and to a method of treating cancer in the individual. The presented invention may be used for treating cancer. The oncolytic adenoviral vector contains a nucleic acid skeleton of serotype 5 adenovirus (Ad5), deletion in 24 nucleotides related to amino acids 122-129 in E1A constant region 2, and a nucleic acid sequence coding the human granulocyte-macrophage colony-stimulating factor (GM-CSF) in a site of deleted gp19k/6.7K in the region E3, and capside modification if needed. |
|
|
Subtype b type 1 iv735 human immunodeficiency viral strain for diagnostic and vaccine preparations Invention refers to a subtype B of a human immunodeficiency viral strain, and can be used in virology, medicine and biotechnology. The presented type 1 IV735 human immunodeficiency viral strain is deposited in the State Collection of Viruses of Federal State Institution Ivanovsky Research Institution of Virology of the Russian Ministry of Healthcare and Social Development, No. 1189. The strain possesses a stable reproductive activity. An infectious titre makes 6 lg 50% tissue cytopathic dose. |
|
|
Antibacterial composition, strain of bacteriophage escherichia coli, used for obtaining thereof Invention relates to field of food industry, biotechnology and deals with antibacterial composition and strain of bacteriophage Escherichia coli, used for obtaining said composition. Characterised composition includes filtrate of Escherichia coli phage lysate, obtained with application of strain of bacteriophage Escherichia coli, deposited in collection of museum of microorganisms of Federal Budget Institution of Science "State Research Centre for Applied Microbiology and Biotechnology" of the Federal Service on Customers' Rights Protection and Human Well-being Surveillance (FBIS SRC AMB of Rospotrebnadzor) under number Ph 64, filtrate of Escherichia coli phage lysate, containing coli bacteriophage, filtrate of staphylococcus phage lysate, filtrate of salmonella phage lysate, filtrate of Listeria monocyctogenes phage lysate and target additives in amount 1.0รท95.0 wt % of composition weight. |
|
|
Subtype a type 1 iv742 human immunodeficiency viral strain for diagnostic and vaccine preparations Invention refers to a subtype A human immunodeficiency viral strain, and can be used in virology, medicine and biotechnology. The presented type 1 IV742 human immunodeficiency viral strain is deposited in the State Collection of Viruses of Federal State Institution Ivanovsky Research Institution of Virology of the Ministry of Healthcare and Social Development of the Russian Federation, No. 1187. The strain possesses a stable reproductive activity. An infectious titre makes 6 lg 50% tissue cytopathic dose. |
|
Invention refers to a subtype A human immunodeficiency viral strain, and can be used in virology, medicine and biotechnology. The presented type 1 IV710 human immunodeficiency viral strain is deposited in the State Collection of Viruses of Federal State Institution Ivanovsky Research Institution of Virology of the Ministry of Healthcare and Social Development of the Russian Federation, No. 1188. The strain possesses a stable reproductive activity. An infectious titre makes 3.5-4.0 lg 50% tissue cytopathic dose. |
|
Method of treating aggravated chronic laryngitis Invention refers to medicine, namely otorhinolaryngology, phoniatrics and physiotherapy and may be used for the integrated treatment of aggravated chronic laryngitis. Starting from the 4-5th day from the aggravation, a standard drug therapy is additionally combined with an endolaryngeal injection of specific pyobacteriophague 1 ml and further exposure to low-frequency vibration covering 3 fields of the larynx and phonopaedic breathing exercises. The low-frequency vibration starts at a first filed comprising side neck surfaces at frequency 20 Hz per 1 filed with a vibratode advanced smoothly upward at 2-3 mm/sec with undisplaced skin and rectangularly up to a mandibular angle, and then downwards to a posterior triangle of neck for 1-2 minutes from each side; the patient does the phonopaedic breathing exercises and pronounces expiratory 'M'; that is followed by the vibrational exposure covering a projection of intersection of a thyroid cartilage plate and a border of sternocleidomastoid muscle (m.sternocleidomastoideus) at a thyroid cartilage notch at frequency 40 Hz and 60 Hz for 1-2 minutes from both sides according to the stable technique; the patient does the phonopaedic breathing exercises and pronounces expiratory vowels 'U', 'O', 'A'; that is followed by vibration of a collar at frequency 30-40 Hz with the vibratode advanced from a paravertebral line to a shoulder joint for 2-3 minutes from each side; the technique is labile. The course performs 8-10 combined daily procedures. |
|
|
Strain is deposited under number Ph 62 in GKPM-Obolensk collection. Strain can be used for development of complex medical and disinfective preparations against infections caused with Staphylococcus aureus, as well as preparations for sanitation of food products against Staphylococcus aureus. |
|
Invention relates to a strain of the bacteriophage Escherichia coli ECD4. The strain of the bacteriophage Escherichia coli ECD4 is isolated from faeces of broiler chickens on the culture of the bacteria of the strain Escherichia coli O104.H4 RK1No.112027 and is deposited in the State Collection of Pathogenic Microorganisms and Cell Cultures "GKPM-Obolensk" under the number Ph63. The proposed strain of the bacteriophage has lytic activity in respect to the bacteria of the strain Escherichia coli O104:H4 RKINo.112027, lyses Escherichia of the serotype 0157:H7, does not suppress growth of cells Escherichia coli M-17, has lytic activity in respect to several other clinically significant serotypes of Escherichia, and also to several types of Shigella. The strain of the bacteriophage Escherichia coli ECD4 propagates on the laboratory non-pathogenic strain Escherichia coli K-12 C600F. |
|
Method of treating acute and aggravated chronic laryngitis Invention refers to medicine and aims at treating acute and aggravated chronic laryngitis. What is involved is specific antibioticotherapy per os with additional examination of microflora starting from the 3rd-5th day of the therapy followed by instillations of specific, result-related bacteriophagues into the larynx in the amount of 0.5-1.0 ml in acute laryngitis for 7-10 days, and in aggravations for 10-14 days. |
|
|
Use of combination of myxoma virus and rapamycin for therapeutic treatment There are offered methods for inhibition of a cancer cell, methods of treating cancer with the use of a combination of myxoma virus or its analogue which expresses no functional M135R, and rapamycin, pharmaceutical compositions and kits containing the combination of myxoma virus or its analogue which expresses no functional M135R, and rapamycin. Rapamycin treatment enhances an ability of myxoma virus to infects the cells selectivity which are characterised by a deficient natural antiviral response, including the cells having no response on interferon. |
|
Pseudomonas aeruginosa bacteriophage strain used as base for preparing aseptic for p aeruginosa What is presented is a very virulent Pseudomonas aeruginosa ph57 bacteriophage strain recovered from vivarium excrement and depositied in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector, registration No. V-357. |
|
|
Method of treating babies suffering intestinal colics Invention refers to medicine, also aims at treating babies suffering intestinal colics. A mother and a breast-fed child are treated simultaneously. A cephalosporin antibiotic, an antistaphylococcal immunoglobulin, a staphylococcal bacteriophage, an antifungal agent, a phagocytosis activator are prescribed in the mother for 7-10 days. A staphylococcal bacteriophage, Hylak forte are prescribed to the baby. The second stage involves prescribing a bacterial preparation, an immunomodulator and a therapeutic staphylococcal anatoxin. The baby intakes Hylak forte and the bacterial preparation. |
|
|
Invention concerns PUUMALA and DOBRAVA viruses strains for preparing , vaccine preparations for specific prevention of hemorrhagic fever and renal syndrome (HFRS). |
|
Invention refers to a strain of human immunodeficiency virus, type one, recombinant subtype 02_AG, and can be used in virology, medicine and biotechnology. Presented strain of human immunodeficiency virus HIV-1 02AG.RU.09RU2410 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-414. |
|
Invention refers to a strain of human immunodeficiency virus, type one, recombinant subtype 02_AG, and can be used in virology, medicine and biotechnology. Presented strain of human immunodeficiency virus HIV-1 02_AG.RU.09RU2308 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-415. |
|
Presented strain of human immunodeficiency virus HIV-1 Al. RU. 09 RU 2255 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-412. |
|
Invention refers to a strain of human immunodeficiency virus, type one, recombinant subtype 02_AG, and can be used in virology, medicine and biotechnology. The presented strain of human immunodeficiency virus HIV-1 02AG.RU.09RU2273 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-392. |
|
Method of treating chronic bacterial conjunctivitis Invention refers to medicine, namely to ophthalmology, and concerns treating chronic bacterial conjunctivitis. That is ensured by bacteriophage instillations in a conjunctival cavity considering drug sensitivity of a bacterial flora. It is combined with nasolacrimal duct irrigation for the first 3-4 days with the bacteriophage preparation, also injected into nasal passages and used to irrigate a pharyngeal mucosa. The therapy is within 10 days, for at least 5 times a day. |
|
|
Presented strain of human immunodeficiency virus HIV-1 02_AG.RU.09RU2383 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-413. |
|
Presented strain of human immunodeficiency virus HIV-1 A1.RU.09RU2240 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-411. |
|
Strain is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-416. |
|
Presented strain of human immunodeficiency virus HIV-1 A1.RU.09RU2225 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-391. |
|
Presented strain of human immunodeficiency virus HIV-1 A1.RU.09RU2065 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-389. |
|
Method of increasing anti-tumour resistance Invention relates to medicine, namely to oncology and can be used for prevention of tumour development. Method includes introduction of influenza vaccine "Grippol", which is preventively introduced subcutaneously in effective amount. |
|
Immunogenic composition based on conditionally live virion and method for making thereof Described is a method for producing conditionally live HIV-1 virions by means of which viral DNA or RNA are modified so that to make virion unable to replication provided a protein supplement has not been added to an expression system. The expression system represents either a conventional cell culture, or a cell-free and vector-free expression system effective in viral particle self-assembly. Both expression systems require viral proteins to be added either for replication, or for assembly of the virion unable to replicaton. The conditionally live virion is used thereafter for creating an immunogenic composition. |
|
Preparation containing staphylococcal bacteriophage, as preparation for candidiasis treatment Invention refers to medicine, particularly to an antimycotic preparation. Application of a preparation containing staphylococcal bacteriophage as virulent bacteriophage and induced-virulence bacteriophage of specified lytic activity in relation to test strains and staphylococcus isolates recovered from human body as a preparation for candidiasis treatment administered orally 2-3 times a day within 4-7 days. |
|
|
Immunobiological bactericidal preparation (versions) According to the invention, the immunobiological bactericidal preparation contains species-specific virulent bacteriophages and induced-virulence bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacteria isolates recovered from a human body in filtrate, concentrate filtrate or in a dry biomass of a phage lysate filtrate of nonlysogenic bacteria and pharmaceutically acceptable desired additives. The preparation can be presented as ointment, suppository, powder, tablet or capsule. Declared immunobiological bactericidal preparation is prepared by sequential multiple passages of phages of bacteriophage preparations through test strains and nonlysogenic bacteria isolates fresh-recovered from a human body with an inducing agent, eg mitomycin C, added to nutrient medium. According to the invention, the immunobiological bactericidal preparation provides stable virulence of bacteriophages and adaptation thereof to circular agents of bacterial infections. |
|
|
Application of myxoma virus for therapeutic treatment of cancer and chronic virus infection Essence of the invention includes a way of inhibition of a mammal cancer cell with the defective antiviral response sensitive to interferon, including introduction of myxoma virus in a cell. The myxoma virus can be used at cancer treatment. |
|
Group of inventions concerns medical virology and microbiology. Bacillus anthracis R/D bacteriophage strain, deposited in collections of microorganism museum of State Research Centre of Applied Microbiology Practical Molecular Biology under serial number Ph-6, is used to produce preparation for anthrax infection diagnostics. Liquid preparation for anthrax infection diagnostics contains suspended particles of bacteriophage Bacillus anthracis R/D-Ph-6 of lytic activity 1010 plaque-forming unit/cm3, 1% quinosol solution, in ratio as follows, wt %: suspended bacteriophage of lytic activity 1010 plaque-forming unit/ml - 10.0-20.0, 1% quinosol solution - 0.5-1.0, physiologic saline - the rest. Dry preparation for anthrax infection diagnostics contains dry solid matter of bacteriophage Bacillus anthracis R/D-Ph-6 of lytic activity 1010 plaque-forming unit/cm3, saccharose, gelatine and quinosol in ratio as follows, wt %: saccharose - 35.0-40.0, gelatine - 6.0-10.0, quinosol - 0.03-0.06, dry solid matter of bacteriophage of lytic activity 1010 plaque-forming unit/cm3 - the rest. |
|
Method of obtaining remedy from fly larvae for wound treatment and remedy obtained by said method Invention relates to field of medicine, namely to remedy and method of obtaining remedy for wound treatment. Method of obtaining remedy for wound treatment lies in the following: from fly eggs larvae are gown, which can be introduced in to wound under treatment, larvae are contaminated with bacteriophages in such way that introduced larvae are bacteriophage carriers. In order to realising said method, in particular, larvae of genus Lucilia are used. Also claimed are method and remedy for wound treatment, with tampon containing bacteriophages and soaked with larva secret on wound. |
|
|
Method of treatment of chronic purulent rhinosinusitis Preparation pyobacteriophage polyvalent purified liquid is injected in maxillary sinus in amount 5-10 ml twice a day, every 12 hours within 6 days. Besides, from the first day of treatment, the preparation is introduced intranasal dosed 3 ml twice a day within 21 days. |
|
In addition to Griseofulvin, Pioployphage is introduced orally in dosage 30-50 ml or on 1-2 tablets twice a day within 14 days. |
|
Method of preventive treatment of nosocomial peritonitis Invention is intended for preventive treatment of nosocomial peritonitis in patients with already developed peritonitis, after applying laparostomy. Stage-by-stage sanation of an abdominal cavity is performed introducing at each sanation, 400 ml of a preparation of bacteriophage active against a potential originator of nosocomial peritonitis. Daily, before putting off laparostomy, 2 times a day 200 ml of the same preparation of bacteriophage is introduced into a gastroenteric tract, at a colon lesion it is introduced through a probe, at a lesion of the top department of a gastroenteric tract through rectum. Additionally, kypherone rectally to all patients in the quantity of 1 suppository 2-3 times a day for 5-10 days. |
|
|
Cell elimination by using viruses Invention relates to uses of viruses capable of reducing undesired cells in ex vivo mixtures of normal marrow or peripheral blood cells and tumor cells, such as leucosis or lymphoma cells due to interaction of abovementioned mixture with vesicular stomatitis virus. Invention also relates to method for malignant tumor treatment in mammalian. Claimed method includes sampling of mammalian marrow or peripheral blood cells; interaction of said cells ex vivo with vesicular stomatitis virus; mieloablative therapy; and transplantation of purified hematopoietic cells into mammalian. In another embodiment invention relates to method for malignant tumor treatment in mammalian having transplant of marrow or peripheral blood stem cells. Said method includes interaction ex vivo of collected transplant cell with vesicular stomatitis virus and administration of these purified cells in mammalian. Method of present invention makes it possible to reduce risk of malignant tumor backset in mammalian with transplanted hematopoietic cells. |
|
|
New bacteriophage strain Helicobacter pylori, having lytic activity is disclosed. Method for production of antigastritis and antiulcer drug based on the new bacteriophage strain also is disclosed. Claimed method includes providing of purified suspension of bacteriophage Helicobacter pylori with lytic activity of 109 FFU/ml and addition of 1 % chinozole thereto. Moreover sorbitole and gelatose also may be introduced into said agent. Obtained mixture is frozen and lyophilized. |
|
|
Method for treating postoperational abscesses of abdominal cavity One should perform generally accepted medicinal therapy, moreover, one should prescribe additional chemotrypsin during the first 1-2 d after operation to be locally injected twice-thrice during day-time period at concentration of 0.5-1.0 mg/ml of 10%-sodium chloride solution at exposure of 1.5-2 h at the quantity of one fourth up to one third against the purulent volume removed out of abscess cavity, then therapy course should be supplemented with bacteriophage which should be locally injected twice during day-time period at daily dosage being 200 ml, not more at exposure of 1.5-2 h at the quantity of one tenth up to one fifth against purulent volume removed out of abscess cavity. As for bacteriophage type, it should be matched in accordance to the results of bacteriological survey of abscess cavitary content. Therapy course lasts for 6-9 d. |
Another patent 2513018.